NovaBay Pharmaceuticals Earnings Estimate

By analyzing NovaBay Pharmaceuticals' earnings estimates, investors can diagnose different trends across NovaBay Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for NovaBay Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options. NovaBay Pharmaceuticals is projected to generate -0.815 in earnings per share on the 31st of December 2024. NovaBay Pharmaceuticals earnings estimates show analyst consensus about projected NovaBay Pharmaceuticals EPS (Earning Per Share). It derives the highest and the lowest estimates based on NovaBay Pharmaceuticals' historical volatility. Many public companies, such as NovaBay Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing NovaBay Pharmaceuticals' earnings estimates, investors can diagnose different trends across NovaBay Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes. At this time, NovaBay Pharmaceuticals' Gross Profit is fairly stable compared to the past year. Gross Profit Margin is likely to rise to 0.80 in 2024, whereas Pretax Profit Margin is likely to drop (0.69) in 2024. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.